Can Nerve Growth Factor (NGF) Be a Treatment Option for Pediatric Eye Diseases?

REFERENCES

• Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987;237(4819):1154–1162. doi:10.1126/science.3306916.
   PubMed Web of Science ®Google Scholar
• Aloe L, Chaldakov GN. Homage to Rita Levi-Montalcini, the queen of modern neuroscience. Cell Biol Int. 2013;37(8):761–765. doi:10.1002/cbin.10098.
   PubMed Web of Science ®Google Scholar
• Micera A, Lambiase A, Aloe L, Bonini S, Levi-Schaffer F, Bonini S. Nerve growth factor involvement in the visual system: implications in allergic and neurodegenerative diseases. Cytokine Growth Factor Rev. 2004;15(6):411–417. doi:10.1016/j.cytogfr.2004.09.003.
   PubMed Web of Science ®Google Scholar
• Lambiase A, Mantelli F, Sacchetti M, Rossi S, Aloe L, Bonini S. Clinical applications of NGF in ocular diseases. Arch Ital Biol. 2011;149(2):283–292. doi:10.4449/aib.v149i2.1363.
   PubMed Web of Science ®Google Scholar
• Chao MV, Hempstead BL. p75 and Trk: a two-receptor system. Trends Neurosci. 1995;18(7):321–326. doi:10.1016/0166-2236(95)93922-K.
   PubMed Web of Science ®Google Scholar
• Romon R, Adriaenssens E, Lagadec C, Germain E, Hondermarck H, Le Bourhis X. Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Mol Cancer. 2010;9(1):157. doi:10.1186/1476-4598-9-157.
   PubMedGoogle Scholar
• Hellweg R, Raivich G, Hd H, Hock C, GW K. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol. 1994;130:24–30.
   PubMed Web of Science ®Google Scholar
• Lambiase A, Bonini S, Micera A, Rama P, Bonini S, Aloe L. Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases. Invest Ophthalmol Vis Sci. 1998;39:1272–1275.
   PubMed Web of Science ®Google Scholar
• Eriksdotter Jonhagen M, Nordberg A, Amberla K, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 1998;9(5):246–257.
   PubMed Web of Science ®Google Scholar
• Chiaretti A, Antonelli A, Genovese O, et al. Intraventricular nerve growth factor infusion improves cerebral blood flow and stimulates doublecortin expression in two infants with hypoxic–ischemic brain injury. Neurol Res. 2008;30(3):223–228. doi:10.1179/016164107X247948.
   PubMed Web of Science ®Google Scholar
• Hammes HP, Federoff HJ, Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med. 1995;1(5):527–534. doi:10.1007/BF03401589.
   PubMed Web of Science ®Google Scholar
• Lambiase A, Aloe L. Nerve growth factor delays retinal degeneration in C3H mice. Graefes Arch Clin Exp Ophthalmol. 1996;234(Suppl S1):S96–100. doi:10.1007/BF02343055.
   PubMedGoogle Scholar
• Lenzi L, Coassin M, Lambiase A, Bonini S, Amendola T, Aloe L. Effect of exogenous administration of nerve growth factor in the retina of rats with inherited retinitis pigmentosa. Vision Res. 2005;45(12):1491–1500. doi:10.1016/j.visres.2004.12.020.
   PubMed Web of Science ®Google Scholar
• Patel A. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47–64.doi:10.5497/wjp.v2.i2.47.
   Google Scholar
• Lambiase A, Tirassa P, Micera A, Aloe L, Bonini S. Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats. Invest Ophthalmol Vis Sci. 2005;46(10):3800–3806. doi:10.1167/iovs.05-0301.
   PubMed Web of Science ®Google Scholar
• Lambiase A, Aloe L, Centofanti M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc Natl Acad Sci U S A. 2009;106(32):13469–13474. doi:10.1073/pnas.0906678106.
   PubMed Web of Science ®Google Scholar
• Lambiase A, Pagani L, Di Fausto V, et al. Nerve growth factor eye drop administrated on the ocular surface of rodents affects the nucleus basalis and septum: biochemical and structural evidence. Brain Res. 2007;1127(1):45–51. doi:10.1016/j.brainres.2006.09.102.
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Mantelli F, Rocco ML, et al. Recombinant human nerve growth factor treatment promotes photoreceptor survival in the retinas of rats with retinitis pigmentosa. Curr Eye Res. 2017;42(7):1064–1068. doi:10.1080/02713683.2017.1279634.
   PubMed Web of Science ®Google Scholar
• Falsini B, Chiaretti A, Barone G, et al. Topical nerve growth factor as a visual rescue strategy in pediatric optic gliomas: a pilot study including electrophysiology. Neurorehabil Neural Repair. 2011;25(6):512–520. doi:10.1177/1545968310397201.
   PubMed Web of Science ®Google Scholar
• Bonini S, Lambiase A, Rama P, et al. Phase I trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125(9):1468–1471. doi:10.1016/j.ophtha.2018.03.004.
   PubMed Web of Science ®Google Scholar
• Bonini S, Lambiase A, Rama P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125(9):1332–1343. doi:10.1016/j.ophtha.2018.02.022.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial. Ophthalmology. 2020;127(1):14–26. doi:10.1016/j.ophtha.2019.08.020.
   PubMed Web of Science ®Google Scholar
• Joo MJ, Kevin R Yuhan, Joon Young Hyon, et al. The effect of nerve growth factor on corneal sensitivity after laser in situ keratomileusi. Arch Ophthalmol. 2004;122(9):1338–1341. doi:10.1001/archopht.122.9.1338.
   PubMedGoogle Scholar
• He J, Neumann D, Kakazu A, et al. PEDF plus DHA modulate inflammation and stimulate nerve regeneration after HSV-1 infection. Exp Eye Res. 2017;161:153–162. doi:10.1016/j.exer.2017.06.015.
   PubMed Web of Science ®Google Scholar
• Mastropasqua L, Lanzini M, Dua HS, et al. In vivo evaluation of corneal nerves and epithelial healing after treatment with recombinant nerve growth factor for neurotrophic keratopathy. Am J Ophthalmol. 2020;217:278–286. doi:10.1016/j.ajo.2020.04.036.
   PubMed Web of Science ®Google Scholar
• Bonini S. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000;107(7):1347–1351. doi:10.1016/S0161-6420(00)00163-9.
   PubMed Web of Science ®Google Scholar
• Ferrari MP, Mantelli F, Sacchetti M, et al. Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial. BioDrugs. 2014;28(3):275–283. doi:10.1007/s40259-013-0079-5.
   PubMed Web of Science ®Google Scholar
• Fausto R, Ceccuzzi R, Micheletti E, et al. A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops. Medicine (Baltimore). 2020;99(30):e20816.
   Google Scholar
• Hatcher JB, Soifer M, Morales NG, Farooq AV, Perez VL, Shieh C. Aftermarket effects of cenegermin for neurotrophic keratopathy in pediatric patients. Ocul Surf. 2021;21:52–57. doi:10.1016/j.jtos.2021.04.003.
   PubMed Web of Science ®Google Scholar
• Leto MG, Toro ME, Indemini PE, et al. Pediatric use of recombinant human nerve growth factor 20 mug/ml eye drops (cenegermin) for bilateral neurotrophic keratopathy in congenital corneal Anesthesia. Cornea. 2021;40(2):228–231. doi:10.1097/ICO.0000000000002612.
   PubMed Web of Science ®Google Scholar
• Papadopoulos K, Besgen V, Sekundo W. Successful treatment of a pediatric neurotrophic keratopathy with cenegermin. Cornea. 2021;40(4):516–518. doi:10.1097/ICO.0000000000002512.
   PubMed Web of Science ®Google Scholar
• Pedrotti E, Bonetto J, Cozzini T, Fasolo A, Marchini G. Cenegermin in Pediatric Neurotrophic Keratopathy. Cornea. 2019;38(11):1450–1452. doi:10.1097/ICO.0000000000002112.
   PubMed Web of Science ®Google Scholar
• Riva I, Micheletti E, Fausto R, et al. Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy. Eur J Ophthalmol. 2021;32(4): 1120672121999344.
   Web of Science ®Google Scholar
• Scelfo C, Mantagos IS. Neurotrophic Keratopathy in Pediatric Patients. Semin Ophthalmol. 2021;36(4):289–295. doi:10.1080/08820538.2021.1896747.
   PubMed Web of Science ®Google Scholar
• Yavuz Saricay L, Bayraktutar B N, Lilley J, Mah F S, Massaro-Giordano M, Hamrah P. (2022). Efficacy of Recombinant Human Nerve Growth Factor in Stage 1 Neurotrophic Keratopathy. Ophthalmology, 129(12), 1448–1450. 10.1016/j.ophtha.2022.08.014
   PubMed Web of Science ®Google Scholar
• Ahuja AS, Bowden FW 3rd, Robben JL, Novel A. Treatment for neurotrophic corneal ulcer using topical cenegermin (OXERVATE) containing recombinant human nerve growth factor. Cureus. 2020;12(11):e11724. doi:10.7759/cureus.11724.
   PubMed Web of Science ®Google Scholar
• Zwingelberg SB, Bachmann BO, Cursiefen C. Real life data on efficacy and safety of topical NGF eye drops (Cenegermin). Klin Monbl Augenheilkd. 2020;237(12):1455–1461. doi:10.1055/a-1274-3675.
   PubMed Web of Science ®Google Scholar
• Bocchini V, Angeletti PU. The nerve growth factor: purification as a 30,000-molecular-weight protein. Proc Natl Acad Sci U S A. 1969;64(2):787–794. doi:10.1073/pnas.64.2.787.
   PubMed Web of Science ®Google Scholar
• Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998;338(17):1174–1180. doi:10.1056/NEJM199804233381702.
   PubMed Web of Science ®Google Scholar
• Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018;66:107–131. doi:10.1016/j.preteyeres.2018.04.003.
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Bruscolini A, Lambiase A. Cenegermin for the treatment of neurotrophic keratitis. Drugs Today (Barc). 2017;53(11):585–595. doi:10.1358/dot.2017.53.11.2722395.
   PubMed Web of Science ®Google Scholar
• Mackie IAF, Roy FH, Meyer SM, eds. Neuroparalytic keratitis. Current Ocular Therapy Philadelphia, PA: WB Saunders. 1995;1995:452–454.
   Google Scholar
• Boland MV, Ervin A-M, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive services task force. Ann Intern Med. 2013;158(4):271–279. doi:10.7326/0003-4819-158-4-201302190-00008.
   PubMed Web of Science ®Google Scholar
• Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795–1809. doi:10.1016/S0140-6736(06)69740-7.
   PubMed Web of Science ®Google Scholar
• Birch DG, Weleber RG, Duncan JL, Jaffe GJ, Tao W. Ciliary neurotrophic factor retinitis pigmentosa study g. randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol. 2013;156(2):283–292 e281. doi:10.1016/j.ajo.2013.03.021.
   PubMed Web of Science ®Google Scholar
• Tirassa P, Rosso P, Iannitelli A. Ocular nerve growth factor (ngf) and ngf eye drop application as paradigms to investigate ngf neuroprotective and reparative actions. Methods Mol Biol. 2018;1727:19–38.
   PubMedGoogle Scholar